This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bernstein Liebhard LLP Investigating Anatabloc Lawsuit Claims Against Manufacturers And Sellers Of Dietary Supplement Purported To Treat Chronic And Incurable Medical Conditions

Stocks in this article: GNC STSI

NEW YORK, Feb. 6, 2014 /PRNewswire/ -- The nationwide law firm of Bernstein Liebhard LLP is now investigating Anatabloc lawsuit ( http://www.consumerinjurylawyers.com/consumer-products/anatabloc-lawsuit/) claims against Star Scientific Inc. (NASDAQ: STSI), Rock Creek Pharmaceuticals, Inc. and GNC Holdings, Inc. (NYSE: GNC), the manufacturers and sellers of Anatabloc dietary supplements. Anatabloc was recently the subject of a warning letter issued by the U.S. Food & Drug Administration (FDA) that asserted claims regarding the ability of anatabine, a key ingredient the product, to treat certain chronic and incurable medical conditions were unfounded.

(Logo:  http://photos.prnewswire.com/prnh/20120202/MM47134LOGO )

"Our Firm is eager to hear from any consumer who purchased Anatabloc dietary supplements. The allegedly misleading statements used by Star Scientific  to promote the sale of this product may entitle those consumers to a refund of the purchase price, as well as other damages," says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who are interested in filing an Anatabloc lawsuit.

Anatabloc FDA Warning Letter

Anatabloc is manufactured by Star Scientific, a wholly-owned subsidiary of Rock Creek Pharmaceuticals, Inc. The product retails for $99.00 per bottle, and is available for sale at GNC, a nationwide chain of health and wellness stores.  A key ingredient in Anatabloc is anatabine, which occurs naturally in cauliflower, eggplant, potatoes, and tomatoes,

On December 20, 2013, the FDA issued a warning letter to Star Scientific which took issue with statements made by the company regarding anatabine's anti-inflammatory properties, specifically its purported ability to mitigate inflammatory bowel disease, ulcerative colitis, Crohn's disease and traumatic brain injury. The FDA warning letter also characterized anatabine as a new drug that requires approval by the FDA.

On December 31, the FDA released a Consumer Alert that specifically noted the warning letter issued to Star Scientific. The purpose of the Alert was to caution the public about companies which offer untested, unproven and possibly dangerous products that claim to prevent, treat or cure concussions and other traumatic brain injuries. According to the agency, these products are not backed by scientific evidence that proves they are safe or effective for such purposes.

Consumers who purchased Anatabloc dietary supplements may be entitled to compensation from the manufacturers and sellers of this product. To learn more about filing an Anatabloc lawsuit, please visit Bernstein Liebhard LLP's website. To obtain a free review of your case, please call (888) 340-4807.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs